Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes

Inclusion Criteria: * GROUP I * Have been clinically diagnosed with type-1 diabetes for at least 1-year * Have an HgbA1c of 7.4% or higher * Treated with short-acting insulin analog (i.e. HumaLog® Lispro, NovoLog® Aspart, Apidra® Glulisine) before each meal and only one injection of long-acting insulin analog Lantus® (Glargine), per day. Subjects must typically eat 3 meals per day. The total daily combined dose of the long-acting and short-acting insulin analogs must be 25 units or more. Patient must have been using the same insulin regimen for the previous 3-months * Is currently using an insulin/carbohydrate ratio to decide how much short-acting insulin to take before meals and must be able to use the gram versus choice method of carbohydrate counting. * GROUP II * Have been clinically diagnosed with type-2 diabetes for at least 1-year * Have an HgbA1c of 7.4% or higher * Treated with short-acting insulin analog (i.e. HumaLog® Lispro, NovoLog® Aspart, Apidra® Glulisine) before each meal and only one injection of long-acting insulin analog Lantus® (Glargine) per day and. Subjects must typically eat 3 meals per day. The total daily combined dose of the long-acting and short-acting insulin analogs must be 25 units or more. Patient must have been using the same insulin regimen for the previous 3-months * May be using other diabetes agent(s) at a stable dose for the last 3-months. * GROUP III * Have been clinically diagnosed with type-2 diabetes for at least 1-year * Have an HgbA1c of 7.8% or higher * Take twice daily biphasic Insulin (e.g. HumaLog® Mix 75/25, NovoLog® Mix 70/30) or premixed insulin (i.e. Humulin® 70/30, Novolin® 70/30, NPH/Regular insulin 70/30) with a total daily insulin dose of 25 units and have been using the same insulin regimen for the past 3-months * May be using other diabetes agent(s) at a stable dose for the last 3-months. Exclusion Criteria: * Have a history of greater than 2 episodes of severe hypoglycemia in the past year, or have hypoglycemic unawareness when glucose levels are less than or equal to 50 mg/dl * Have a significant physical, psychological, or cognitive impairment that would prohibit adherence to the protocol * Have any severe cardiovascular disease including a history of congestive heart failure (New York Heart Association \[NYHA\] 3 or 4), unstable angina, myocardial infarction or stroke that occurred within the 6-months preceding enrollment * Have known active anemia with a hemotocrit less than 25% in women or 30% in men * Have known history of renal disease (e.g., serum creatinine level \>2.0 mg/dl or eGFR \< 30 ml/min) * Have active cancer or cancer in the past 2-years (except non-melanoma skin cancer * Have history of significant liver disease including cirrhosis or elevated liver enzymes (e.g., AST and ALT greater than 3 times the upper limit of normal values) * Have a body mass index (BMI) \> 45 kg/m2; and/or * Are pregnant, plan to become pregnant during the study period, or are breastfeeding.